Price$5.42-0.09 (-1.63%)
01:30 PM04:15 PM
News · 26 weeks51-72%
2025-12-282026-06-21
Mix3990d
- Insider20(51%)
- SEC Filings9(23%)
- Other7(18%)
- Earnings2(5%)
- Leadership1(3%)
Latest news
25 items- SECCertara Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Certara, Inc. (0001827090) (Filer)
- PRCertara Announces CFO TransitionRADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effective as of the end of the day on July 14, 2026. Concurrently, Certara has launched a search with a leading executive search firm to identify the Company's next Chief Financial Officer. Faiz Mohammed, Certara's Senior Vice President of Finance and Treasurer, has agreed to serve as Interim CFO upon Mr. Gallagher's departure until a successor is named and appointed. Mr. Mohammed has been a finance leader with Certara since 2018 and brings mo
- PRThe Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItIssued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually
- INSIDERChief Human Resources Officer Anhalt Rona converted options into 7,147 shares and covered exercise/tax liability with 2,241 shares, increasing direct ownership by 41% to 16,789 units (SEC Form 4) (withholding tax)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSVP and General Counsel Corcoran Daniel converted options into 22,830 shares and covered exercise/tax liability with 12,103 shares, increasing direct ownership by 50% to 32,046 units (SEC Form 4) (for tax liability)4 - Certara, Inc. (0001827090) (Issuer)
- PRCertara to Participate in Upcoming Investor ConferencesRADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: RBC CM Global Healthcare ConferenceDate and Time: Tuesday, May 19 at 9:30 a.m. ET William Blair's 46th Annual Growth Stock ConferenceDate: Tuesday, June 2 Jefferies Global Healthcare ConferenceDate: Wednesday, June 3 at 1:20 p.m. ET Live webcasts for the RBC and Jefferies conferences will be available on Certara's investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter. About CertaraCertara accelerates me
- SECSEC Form 8-K filed by Certara Inc.8-K - Certara, Inc. (0001827090) (Filer)
- INSIDERDirector Bedi Arjun converted options into 5,547 shares (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERChairman Broshy Eran converted options into 15,757 shares, increasing direct ownership by 45% to 50,708 units (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERChief Financial Officer Reynders John V W converted options into 15,757 shares, increasing direct ownership by 147% to 26,466 units (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Certara Inc.4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERDirector Killefer Nancy converted options into 15,757 shares, increasing direct ownership by 44% to 51,846 units (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERChairman Cashman James E Iii converted options into 15,757 shares, increasing direct ownership by 3% to 484,197 units (SEC Form 4)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT, PREDICTIVE TECH Aspbury Robert4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by PRESIDENT, CHIEF COMMERCAL OFF Pedersen Leif E4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Chief Human Resources Officer Anhalt Rona4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERChief Executive Officer Resnick Jon Matthew converted options into 59,766 shares and covered exercise/tax liability with 24,377 shares (SEC Form 4) (withholding tax)4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by SVP and General Counsel Corcoran Daniel4 - Certara, Inc. (0001827090) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Gallagher John E4 - Certara, Inc. (0001827090) (Issuer)
- SECSEC Form 10-Q filed by Certara Inc.10-Q - Certara, Inc. (0001827090) (Filer)
- SECCertara Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Certara, Inc. (0001827090) (Filer)
- PRCertara Reports First Quarter 2026 Financial ResultsRADNOR, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today reported its first quarter 2026 financial results. First Quarter Highlights: Revenue was $106.9 million, compared to $106.0 million in the first quarter of 2025, representing growth of 1%. Software revenue was $49.7 million, compared to $46.4 million in the first quarter of 2025, representing growth of 7%.Services revenue was $57.2 million, compared to $59.6 million in the first quarter of 2025, representing a decrease of 4%. Net loss was $8.8 million, compared to a net income of $4.7 million in the first quarter of 2025, representing a decrease of 285%.A
- PRAltasciences and Certara Announce Strategic Partnership to Accelerate Early Drug DevelopmentAltasciences, a fully integrated drug development solution company, and Certara (NASDAQ:CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences' Acceleration Platform, the integration of Certara's strategic drug development services and biosimu
- SECSEC Form D filed by Certara Inc.D - Certara, Inc. (0001827090) (Filer)
- SECCertara Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Certara, Inc. (0001827090) (Filer)
CERT FAQ
7 questionsWhat does Certara Inc. do?
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and...Where does CERT stock trade?
Certara Inc. (CERT) is listed on NASDAQ.What sector and industry is CERT in?
Certara Inc. operates in the Technology sector, Computer Software: Prepackaged Software industry.When did Certara Inc. go public?
Certara Inc. (CERT) completed its IPO in 2020.What are analysts saying about CERT?
Certara Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Equal Weight with a $800.00 price target on 2026-03-06. Recent price targets range from $800.00 to $1600.00.What companies are similar to CERT?
Notable peers in the same industry include MSFT (Microsoft Corporation), ORCL (Oracle Corporation), SAP (SAP SE), CRWD (CrowdStrike Holdings Inc.), CRM (Salesforce Inc.). Compare CERT side-by-side with any of them on Quantisnow.How can I track CERT on Quantisnow?
Quantisnow aggregates Certara Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CERT to receive live email and push alerts on every new disclosure.